Przejdź do zawartości
Merck

How long should patients remain in the supine treatment position after intratympanic dexamethasone injection?

The Laryngoscope (2014-08-12)
Soon H Park, Changhun Park, Jin Y Seo, Jae H Cho, In S Moon
ABSTRAKT

Intratympanic dexamethasone injection (ITDI) is a widely accepted treatment for patients with sudden hearing loss. We investigated the appropriate patient wait time in the supine treatment position after ITDI. Prospective study. In an in vivo animal study, 24 mice were injected intratympanically with dexamethasone. Perilymphatic fluid was sampled at 5, 10, 15, 20, 25, and 30 minutes postinjection. The dexamethasone concentration was analyzed using high-performance liquid chromatography. In a separate prospective clinical study, 79 patients with refractory sudden hearing loss underwent intratympanic injection. After the injection, patients remained in the supine position with the head rotated 45° to the unaffected side. Patients were divided into two groups according to the wait time in this treatment position postinjection: 30 minutes (n = 47) and 10 minutes (n = 32). Final hearing assessments were conducted 2 months after salvage treatment. In the in vivo animal study, the perilymphatic concentration of dexamethasone showed no significant increase after 10 minutes. In the clinical setting, hearing improvement according to Siegel's criteria was similar in the 30-minute (14/47) and 10-minute (10/32) groups (P = 0.999). No significant differences in relative hearing gain was observed between the two groups (13.80 ± 19.9 dB and 12.57 ± 14.9 dB, respectively; P = 0.766). We suggest that 10 minutes is a sufficient time to remain in the supine treatment position after ITDI in patients with sudden hearing loss. N/A.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material
Prednisolone, European Pharmacopoeia (EP) Reference Standard
USP
Prednisolone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Prednisolone, ≥99%
Sigma-Aldrich
Xylazine hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
Dexamethasone 21-phosphate disodium salt, ≥98%
Supelco
Prednisolone, VETRANAL®, analytical standard
Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard
Xylazine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Prednisolone, British Pharmacopoeia (BP) Assay Standard
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Supelco
Dexamethasone, VETRANAL®, analytical standard
Prednisolone for peak identification, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Dexamethasone sodium phosphate for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Dexamethasone sodium phosphate, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard